NuVasive (NUVA) - FREE Research Report

Lukianov Alexis V who is Chairman & CEO at NuVasive sold 4,800 shares at $35.16 on Jan. 13, 2014. Following this transaction, the Chairman & CEO owned 50,940 shares meaning that the stake was reduced by 8.61% with the 4,800-share transaction.

The shares most recently traded at $33.95, down $1.21, or 3.57% since the insider transaction. Historical insider transactions for NuVasive go as follows:

  • 4-Week # shares sold: 48,346
  • 12-Week # shares sold: 84,234
  • 24-Week # shares sold: 121,881

The average volume for NuVasive has been 445,800 shares per day over the past 30 days. NuVasive has a market cap of $1.6 billion and is part of the health care sector and health services industry. Shares are up 4.79% year-to-date as of the close of trading on Monday.

NuVasive, Inc., a medical device company, engages in the design, development, and marketing of minimally disruptive surgical products and procedurally integrated solutions for the spine. The company's products focus on applications for spine fusion surgery. Currently there are 7 analysts that rate NuVasive a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NUVA - FREE

TheStreet Quant Ratings rates NuVasive as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and impressive record of earnings per share growth. However, as a counter to these strengths, we find that the company's return on equity has been disappointing. Get the full NuVasive Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Why the World Isn't Ending: Market Recon

Cramer: Are You Paying Attention to These Boring Companies? You Should

Time to Nail Down Some Profits on Nordson

Cramer: Are You Paying Attention to These Boring Companies? You Should